We are live on ! Find out more
ABG

Ally Bridge Group Portfolio holdings

AUM $124M
1-Year Est. Return 249.88%
This Fund
S&P 500
This Quarter Est. Return
+0.68%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$340M
AUM Growth
-$62.4M
Cap. Flow
-$7.23M
Cap. Flow %
-2.13%
Top 10 Hldgs %
54.94%
Holding
37
New
8
Increased
4
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
SGHT icon
Sight Sciences
SGHT
+$11.3M
2
RPID icon
Rapid Micro Biosystems
RPID
+$9.05M
3
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
+$9.02M
4
CELL
PhenomeX Inc. Common Stock
CELL
+$7.68M
5
MGNX icon
MacroGenics
MGNX
+$6.07M

Top Sells

Rank Stock Value
1
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$17.3M
2
EPIX
ESSA Pharma
EPIX
+$10.4M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$8.02M
4
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
+$5.74M
5
APLS
Apellis Pharmaceuticals
APLS
+$4.78M

Sector Composition

Rank Sector Weight
1 Healthcare 85.19%
2 Materials 1.42%
3 Financials 1.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYPH
26
Cypherpunk Technologies Inc
CYPH
$66.2M
$4.81M 1.41%
+120,000
New +$2.26M
ISEE
27
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$4.06M 1.19%
+250,000
New +$2.72M
CELL
28
DELISTED
PhenomeX Inc. Common Stock
CELL
$3.95M 1.16%
+201,996
New +$7.68M
ACET icon
29
Adicet Bio
ACET
$72.8M
$3.33M 0.98%
26,563
– –
BOLT icon
30
Bolt Biotherapeutics
BOLT
$7.36M
$3.25M 0.96%
12,863
-7,750
-38% -$2.19M
VERV
31
DELISTED
Verve Therapeutics
VERV
$705K 0.21%
+15,000
New +$882K
APLS
32
DELISTED
Apellis Pharmaceuticals
APLS
– –
-85,000
Closed -$4.78M
AVIR icon
33
Atea Pharmaceuticals
AVIR
$379M
– –
-373,288
Closed -$8.02M
EPIX
34
DELISTED
ESSA Pharma
EPIX
– –
-363,185
Closed -$10.4M
SPRY icon
35
ARS Pharmaceuticals
SPRY
$590M
– –
-128,572
Closed -$3.97M
CERE
36
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-675,670
Closed -$17.3M
FRLN
37
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
– –
-26,783
Closed -$3.27M
1
2

Similar funds

MP
Marcho Partners London, United Kingdom $124M AUM 15.03% 1-Year Est. Return
EWP
E-Wealth Partners Minnetonka, Minnesota $124M AUM
WFA
WJ Financial Advisors Killingworth, Connecticut $124M AUM
VWM
Vigil Wealth Management Ponte Vedra Beach, Florida $124M AUM
EI
EDMP Inc Lutz, Florida $124M AUM 19.53% 1-Year Est. Return
TC
Town Capital Bel Air, Maryland $124M AUM
IFO
Intrepid Family Office Sarasota, Florida $124M AUM 37.91% 1-Year Est. Return
CRW
Clarity Retirement & Wealth New Bedford, Massachusetts $124M AUM

Ally Bridge Group's Q3 2021 Portfolio in Review

As of Q3 2021, Ally Bridge Group held 37 positions worth $340M, down 16% from $403M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Ally Bridge Group's Q3 2021 filing shows 8 new, 4 increased, 7 reduced and 6 closed positions. Its largest new stake was Sight Sciences: 342,304 shares worth $7.77M. The largest sale was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $17.3M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 86% a quarter earlier, followed by Materials and Financials.

  • Ally Bridge Group's largest Q3 2021 buy was Sight Sciences: 342,304 shares worth $7.77M.
  • Ally Bridge Group added most to MacroGenics in Q3 2021, an estimated $6.07M increase.
  • Ally Bridge Group's biggest Q3 2021 reduction was Cyteir Therapeutics, Inc. Common Stock, cutting an estimated $5.74M.
  • Ally Bridge Group fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2021, selling an estimated $17.3M.
  • Ally Bridge Group's ten largest holdings make up 55% of its $340M portfolio in Q3 2021.
  • Ally Bridge Group opened 8 new positions and closed 6 in Q3 2021.
  • Ally Bridge Group's portfolio value fell 16% quarter-over-quarter to $340M.

Based on Ally Bridge Group's 13F filing for Q3 2021, filed 15 Nov 2021.